XSpray Pharma AB
6XP
Company Profile
Business description
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
Contact
Scheeles vag 2
SolnaSE-171 65
SWET: +46 87303700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
27
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,464.20 | 42.50 | 0.50% |
| CAC 40 | 7,694.44 | 67.60 | 0.89% |
| DAX 40 | 23,352.69 | 236.73 | 1.02% |
| Dow JONES (US) | 41,368.45 | 254.48 | 0.62% |
| FTSE 100 | 8,531.61 | 27.72 | -0.32% |
| HKSE | 22,778.63 | 2.71 | 0.01% |
| NASDAQ | 17,928.14 | 189.98 | 1.07% |
| Nikkei 225 | 37,476.25 | 547.62 | 1.48% |
| NZX 50 Index | 12,605.07 | 138.04 | 1.11% |
| S&P 500 | 5,663.94 | 32.66 | 0.58% |
| S&P/ASX 200 | 8,234.10 | 42.40 | 0.52% |
| SSE Composite Index | 3,344.19 | 7.81 | -0.23% |